Ljubljana University Medical Centre

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, Multimedia, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care

Retrieved on: 
Thursday, November 11, 2021
LLY, Edmonton protocol, Form, Private Securities Litigation Reform Act, Endocrinology, United States Department of Health and Human Services, Pediatrics, Education, Cell Transplantation, Alex: The Life of a Child, Adolescence, Disease, Doctor of Philosophy, Department, Endocrine Society, CDE, Diabetes, Centers for Disease Control and Prevention, Research, Multimedia, Facebook, Insulin, Twitter, Conditional sentence, Eli Lilly and Company, World Diabetes Day, U.S. Securities and Exchange Commission, Consultant, Center, GA, NYSE, Ljubljana University Medical Centre, Human services, Adult, Pharmaceutical industry, Medicine, Risk management

The Leonard Award was inspired by the life of Leonard Thompson, the first person with diabetes to be treated with insulin in 1922, and celebrates ongoing achievements in the diabetes community.

Key Points: 
  • The Leonard Award was inspired by the life of Leonard Thompson, the first person with diabetes to be treated with insulin in 1922, and celebrates ongoing achievements in the diabetes community.
  • Diabetes educator/nurse: Vanita Pais, RD, CDE of Toronto, Ontario, Canada, for work on food skills programs and workshops for children with type 1 diabetes.
  • The winners from each category were selected by an external judges' panel comprised of esteemed leaders in diabetes care.
  • Lillyhas been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin.